1-6 of 6
Joanne Willey
Close
Sort by
Journal Articles

Current Real-World Treatment Patterns and Outcomes in Patients with Relapsed/Refractory Multiple Myeloma

Jenny Willson, Amanda Bruno, Joanna Opalinska, Jeannene Nelson, Orsolya Lunacsek, Dana Stafkey-Mailey, Joanne Willey
Journal: Blood
Blood (2018) 132 (Supplement 1): 3290.
https://doi.org/10.1182/blood-2018-99-112954
Published: 2018
Journal Articles

Progression-Free Survival in Third-Line Treatment of Relapsed/Refractory Multiple Myeloma Among Patients with Who Have Received Prior Bortezomib and Immunomodulatory Drugs

Sundar Jagannath, MD, Anuja Roy, PhD, Jonathan K Kish, PhDMPH, Denise Globe, PhD, Orsolya Lunacsek, PhDMBA, Michael T. Eaddy, PharmD, PhD, Emil T Kuriakose, MD, Joanne Willey, RN, David Siegel, MD PhD
Journal: Blood
Blood (2015) 126 (23): 3311.
https://doi.org/10.1182/blood.V126.23.3311.3311
Published: 2015
Journal Articles

Trends in First Line Prescribing Preferences Among US-Based Hematology-Oncology Physicians for Patients with Multiple Myeloma Who Are Not Candidates for or Elect Not to Undergo Stem Cell Transplant

Joel H Schwartz, MD, Joanne Willey, RN, Arden Buettner, Mitch Scharf, Maria Lankford, Mark R. Green, MD, Katarzyna Puto, PharmD, MBA
Journal: Blood
Blood (2014) 124 (21): 5776.
https://doi.org/10.1182/blood.V124.21.5776.5776
Published: 2014
Journal Articles

First-Line Prescribing Preferences of U.S. Hematology-Oncology Physicians for Patients with CLL: Impact of Novel Agents

Mark R. Green, MD, Michael E. Williams, MD, Joanne Willey, RN, Arden Buettner, Douglas Neely, Maria Lankford
Journal: Blood
Blood (2014) 124 (21): 4676.
https://doi.org/10.1182/blood.V124.21.4676.4676
Published: 2014
Journal Articles

First-Line Prescribing Preferences of American Hematology-Oncology Physicians for Patients with CLL: Impact of Age, Co-Morbidities, and Tempo of Disease

Mark R. Green, MD, Michael E. Williams, MD, Joanne Willey, RN, Mitchell Scharf, Douglas Neely, Michael G. Heckman, MS, James M. Foran, MD, FRCPC
Journal: Blood
Blood (2012) 120 (21): 4608.
https://doi.org/10.1182/blood.V120.21.4608.4608
Published: 2012
Journal Articles

Treatment of Higher-Risk Myelodysplastic Syndrome (MDS) by American Hematology-Oncology Providers (AHOP's): Changes in 1st-Line Treatment Preferences Over Time in Relation to Cytogenetics & Survival Data From Randomized Studies (2006–2010),

James M. Foran, MD, FRCPC, Michael G. Heckman, MS, Michael E. Williams, MD, Joanne Willey, RN, Mark R. Green, MD
Journal: Blood
Blood (2011) 118 (21): 3816.
https://doi.org/10.1182/blood.V118.21.3816.3816
Published: 2011